Bioequivalence Studies Simulators Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Bioequivalence Studies Simulators Market is Segmented By Study Type (Bioavailability Studies, Single Dose Studies, Multidose Studies, Comparative End Point Studies), By Application (Cardiovascular Disease, Oncology, CNS Disorders, Infectious Diseases, Other), By End User (Pharmaceutical Companies, Research Institutes, Contract Research Organizations), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Bioequivalence Studies Simulators Market Overview

Global Bioequivalence Studies Simulators market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Virtual bioequivalence studies (VBE) can evaluate the resemblance and probable discrepancies in pharmacokinetic and clinical interpretation between test and reference formulations established on the translational association between in vitro, in silico, and in vivo. The essential information from clinical investigations can be provided with the aid of virtual bioequivalence investigation, which intends to hasten up the design of novel and generic medications.

Bioequivalence Studies Simulators Market Scope

For more details on this report Request for Sample

Bioequivalence Studies Simulators Market Dynamics: Drivers & Restraints

Increasing Demand for Generic Drugs

The global market growth is expected to receive a boost due to the increasing demand for generic drugs during the forecast period. As per the National Institutes of Health (NIH), American consumers spend around $103 billion per year on generic drugs. Upon receiving approval from the Food and Drug Administration (FDA), generic drugs are considered to be almost perfect substitutes for the high-priced branded products they replicate. Furthermore, according to the United States Food and Drug Administration, 9 out of 10 prescriptions filled in the United States are for generic drugs. 

Additionally, the rise in infectious and chronic diseases and growing research activities are among other factors that are expected to contribute to the global market growth during the forecast period.

Problems Associated with Bioequivalence Studies

The problems associated with bioequivalence studies such as high variability, very poorly absorbed drugs, and endogenous substances with their own baseline among others are expected to hamper the global market growth during the forecast period. Furthermore, high cost and a deficient number of skilled professionals are among the additional factors hampering the global market growth during the forecast period.

Bioequivalence Studies Simulators Market Segmentation

The global bioequivalence studies simulators market is segmented based on study type, application, end user and region.

Bioavailability Study Type is Expected to Dominate Market

The bioavailability study type is expected to dominate the global market during the forecast period due to the increase in product introductions. For instance in February 2021, Simulations Plus, Inc., a top provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, released the version 9.8.1 of its flagship physiologically based biopharmaceutics (PBBM)/ pharmacokinetics (PBPK) modeling program, GastroPlus, . Additionally, in October 2021, the company announced the release of version 9.8.2 of the same program.

Global Bioequivalence Studies Simulators Market Geographical Share

North America is Expected to Dominate the Global Market

Owing to the increasing grants from the government to validate and define best practices for physiologically based biopharmaceutics/pharmacokinetics (PBBM/PBPK) modeling workflows to simulate virtual bioequivalence (VBE) investigations in support of regulatory biowaivers in North America the region is estimated to dominate the global market during the forecast period. 

For instance, in November 2022, Simulations Plus, Inc., a top provider of modeling and simulation software and services for pharmaceutical safety and efficacy, acquired a new sponsored contract from the U.S. Food and Drug Administration (FDA) as a collaborative proposal with the University of Florida’s College of Pharmacy to promote in vitro and (patho)physiology-based pharmacokinetics (PBPK) prototypes to comprehend and predict pulmonary absorption and tissue retention of inhaled drugs. Again, in September 2023, Simulations Plus, Inc. obtained a new funded grant from the U.S. Food and Drug Administration (FDA).

COVID-19 Impact Analysis

The COVID-19 pandemic has underscored the importance of speed and safety in drug development. The bioequivalence studies simulators are providing researchers with the ability to evaluate repurposing of existing drugs, predict drug-drug interactions, and perform virtual bioequivalence assessments with an increasing variety of dosing routes. Thus, the pandemic has led to increase in the adoption of the bioequivalence studies simulators, positively impacting the global market.

Key Developments

• In October 2020, Simulations Plus, Inc., the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, introduced version 9.8 of its flagship platform for physiologically based biopharmaceutics (PBBM) / pharmacokinetic (PBPK) modeling, GastroPlus. 
• In January 2021, Certara, Inc., the global leader in biosimulation, introduced version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform.

Bioequivalence Studies Simulators Market Companies

The major global players in the market include Simulations Plus, Inc., Certara, Inc., Pumas-AI, Inc., BioPharma Services Inc., and Open Systems Pharmacology among others.

Why Purchase the Report?

• To visualize the global bioequivalence studies simulators market segmentation based on study type, application, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of bioequivalence studies simulators market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bioequivalence studies simulators market report would provide approximately 46 tables, 55 figures and 180 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies